Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...
News Medical on MSN
Blood test offers hope for more effective ovarian cancer treatment: Study
More than 300,000 women are diagnosed with ovarian cancer globally each year. The four-year clinical trial across 15 ...
BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...
Myriad Genetics, Inc. MYGN recently announced the expansion of a strategic partnership with Illumina Inc. ILMN to widen access to oncology homologous recombination deficiency (HRD) testing in the ...
Tesaro has made a deal with Myriad Genetics to use Myriad's homologous recombination deficiency (HRD) test to look for tumor types that may respond to its poly-ADP ribose polymerase (PARP) inhibitor, ...
CHICAGO, May 31, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of ...
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...
QIAGEN N.V. QGEN, together with Myriad Genetics MYGN, will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The endeavor expands upon the ...
The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer The efficiency of the Myriad Homologous ...
Myriad Genetics, Inc. MYGN today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct ...
Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback